Clinical Trials Logo

Filter by:
NCT ID: NCT03422042 Completed - Clinical trials for Common Bile Duct Calculi

Short Duration Versus Fourteen Days Antibiotic in Common Bile Duct Cholangitis

Start date: August 13, 2017
Phase: N/A
Study type: Interventional

Common bile duct stone cholangitis is a potentially fatal condition, characterized by an obstruction and bacterial infection of biliary system. The principles of management are appropriate biliary drainage and systemic antibiotics. There has been limited data about appropriate time of antibiotics in patient with successful endoscopic drainage.

NCT ID: NCT03421340 Completed - Biliary Stones Clinical Trials

Non-Complex Biliary Stones DSC vs ERC

Start date: September 21, 2018
Phase: N/A
Study type: Interventional

To prospectively compare non-complex biliary stone clearance using fluoroscopy/radiation-free direct solitary cholangioscopy (DSC) utilizing the SpyGlass™ system with non-complex biliary stone clearance using standard endoscopic retrograde cholangiography (ERC).

NCT ID: NCT03420781 Terminated - Diabetes Mellitus Clinical Trials

A Safety and Efficacy Study of Relamorelin in Diabetic Gastroparesis Study 03

Start date: January 24, 2018
Phase: Phase 3
Study type: Interventional

A 46-week study to compare the efficacy of relamorelin with that of placebo in participants with diabetic gastroparesis (DG). At the end of the 40-week Treatment Period, participants will either continue on relamorelin or placebo for 6 additional weeks.

NCT ID: NCT03412500 Recruiting - Clinical trials for Methicillin-Resistant Staphylococcus Aureus

Vancomycin Dosage Adjustment for MRSA Infections

Start date: October 2016
Phase: Phase 4
Study type: Interventional

An open-label randomized controlled trial to compare two vancomycin dosage adjustment methods

NCT ID: NCT03411538 Completed - Clinical trials for Hospital-acquired Infections

Mortality Related to AMR in Patients With Hospital-acquired Infection

HAMR
Start date: March 1, 2018
Phase:
Study type: Observational

This is a prospective surveillance study to estimate excess deaths due to and risk factors associated with antibiotic-resistant infection among patients with hospital-acquired infection (HAI) in a resource-limited setting. We will focus on six pathogenic bacteria that are of clinically important in the hospital.

NCT ID: NCT03409679 Terminated - Pneumonia Clinical Trials

Pivotal Study in VAP Suspected or Confirmed to be Due to Pseudomonas Aeruginosa

PRISM-MDR
Start date: March 23, 2018
Phase: Phase 3
Study type: Interventional

This is a phase 3, multicenter, open-label, randomized active-controlled, parallel group to investigate the efficacy, safety and tolerability, and pharmacokinetics of intravenous murepavadin combined with of one anti-pseudononas antibiotic with that of two anti-pseudomonas antibiotics in the treatment of ventilator-associated bacterial pneumonia (VABP) in adult subjects.

NCT ID: NCT03409614 Active, not recruiting - Clinical trials for Non-small Cell Lung Cancer

Combinations of Cemiplimab (Anti-PD-1 Antibody) and Platinum-based Doublet Chemotherapy in Patients With Lung Cancer

Start date: March 6, 2018
Phase: Phase 3
Study type: Interventional

The primary objectives of this study are: Part 1: To compare the overall survival (OS) of cemiplimab/chemo-f and cemiplimab/chemo-l/ipi versus platinum-based doublet chemotherapy in the first-line treatment of patients with advanced squamous or nonsquamous non-small cell lung cancer (NSCLC) with tumors expressing PD-L1 in <50% of tumor cells. Part 2: To compare the OS of cemiplimab/chemo-f with placebo/chemo-f in the first-line treatment of patients with advanced squamous or non-squamous NSCLC irrespective of PD-L1 expression. The key secondary objectives are: Part 1: To compare the progression-free survival (PFS) and objective response rate (ORR) of cemiplimab/chemo-f and cemiplimab/chemo-l/ipi versus chemo-f in the first-line treatment of patients with advanced squamous or non-squamous NSCLC and tumors expressing PD-L1 in <50% of tumor cells. Part 2: To compare the PFS and ORR of cemiplimab/chemo-f versus placebo/chemo-f in the first-line treatment of patients with advanced squamous or non-squamous NSCLC irrespective of PD-L1 expression.

NCT ID: NCT03405597 Recruiting - Clinical trials for Chronic Hepatitis B, HBsAg, Hepatitis B Vaccine

HBsAb Response After HBV Vaccination in Chronic Hepatitis B Patients Who Have Lost HBsAg

Start date: March 30, 2017
Phase: Phase 3
Study type: Interventional

Chronic HBV infection is major problem in Asian countries. Years after chronic infection, in some cases serum HBsAg level declines to unmeasurable level. Some of patients develop anti-HBsAb but there is no standard treatment to accelerate HBsAg seroconversion. There is a study to determine efficacy and safety of HBV vaccine in who is Chronic HBV infection and lost their HBsAg without seroconversion to anti-HBsAb.

NCT ID: NCT03397680 Active, not recruiting - Clinical trials for Helicobacter Pylori Infection

Effectiveness of Once-daily Dose Regimen of 7-day and 14-day High Dose Rabeprazole-levofloxacin Based Quadruple Therapy for H. Pylori Eradication in Thai Patients With Non-ulcer Dyspepsia

Start date: May 15, 2017
Phase: Phase 1
Study type: Interventional

H.pylori is an organism which causes gastric inflammation, peptic ulcer disease (PUD), mucosa associated lymphoid tissue (MALT) lymphoma and gastric cancer. Practical guideline for treatment of patients with dyspepsia and H.pylori eradication recommended the 14-day triple therapy regimen which had curable about 70% by using proton pump inhibitor (PPI) combined with antibiotics including amoxicillin, clarithromycin and metronidazole. Up to date, there has been no evidence about the cure rate for H.pylori eradication with once-daily dose regimen of high dose rabeprazole and levofloxacin based therapy. This research is to study the 7-day and 14-day cure rate of H.pylori eradication treatment with once-daily regimen of high dose rabeprazole-levofloxacin based quadruple therapy.

NCT ID: NCT03394235 Completed - Clinical trials for Androgenetic Alopecia

Optimizing Parameters for Long-pulsed Nd:YAG Laser for Reducing Hair Shaft Diameter

Start date: February 2, 2018
Phase: N/A
Study type: Interventional

This study evaluates the optimizing parameters of long pulse Nd:YAG Laser for reducing the size of hair shaft diameter of the donor for hair transplantation. All participants will receive long-pulsed Nd-YAG laser treatments with three different parameters at the occipital area.